QQQ   430.88 (-0.04%)
AAPL   169.52 (-1.84%)
MSFT   415.90 (+0.55%)
META   500.90 (+0.13%)
GOOGL   154.10 (-0.49%)
AMZN   184.01 (+0.21%)
TSLA   156.46 (-3.11%)
NVDA   870.30 (+1.20%)
AMD   163.62 (+2.06%)
NIO   3.80 (-2.31%)
BABA   69.63 (-1.40%)
T   16.00 (-1.48%)
F   12.05 (-1.47%)
MU   120.13 (-1.02%)
GE   154.13 (+0.28%)
CGC   6.67 (-4.44%)
DIS   113.58 (+0.56%)
AMC   2.60 (+5.26%)
PFE   25.90 (-0.04%)
PYPL   63.66 (+0.24%)
XOM   118.79 (-0.74%)
QQQ   430.88 (-0.04%)
AAPL   169.52 (-1.84%)
MSFT   415.90 (+0.55%)
META   500.90 (+0.13%)
GOOGL   154.10 (-0.49%)
AMZN   184.01 (+0.21%)
TSLA   156.46 (-3.11%)
NVDA   870.30 (+1.20%)
AMD   163.62 (+2.06%)
NIO   3.80 (-2.31%)
BABA   69.63 (-1.40%)
T   16.00 (-1.48%)
F   12.05 (-1.47%)
MU   120.13 (-1.02%)
GE   154.13 (+0.28%)
CGC   6.67 (-4.44%)
DIS   113.58 (+0.56%)
AMC   2.60 (+5.26%)
PFE   25.90 (-0.04%)
PYPL   63.66 (+0.24%)
XOM   118.79 (-0.74%)
QQQ   430.88 (-0.04%)
AAPL   169.52 (-1.84%)
MSFT   415.90 (+0.55%)
META   500.90 (+0.13%)
GOOGL   154.10 (-0.49%)
AMZN   184.01 (+0.21%)
TSLA   156.46 (-3.11%)
NVDA   870.30 (+1.20%)
AMD   163.62 (+2.06%)
NIO   3.80 (-2.31%)
BABA   69.63 (-1.40%)
T   16.00 (-1.48%)
F   12.05 (-1.47%)
MU   120.13 (-1.02%)
GE   154.13 (+0.28%)
CGC   6.67 (-4.44%)
DIS   113.58 (+0.56%)
AMC   2.60 (+5.26%)
PFE   25.90 (-0.04%)
PYPL   63.66 (+0.24%)
XOM   118.79 (-0.74%)
QQQ   430.88 (-0.04%)
AAPL   169.52 (-1.84%)
MSFT   415.90 (+0.55%)
META   500.90 (+0.13%)
GOOGL   154.10 (-0.49%)
AMZN   184.01 (+0.21%)
TSLA   156.46 (-3.11%)
NVDA   870.30 (+1.20%)
AMD   163.62 (+2.06%)
NIO   3.80 (-2.31%)
BABA   69.63 (-1.40%)
T   16.00 (-1.48%)
F   12.05 (-1.47%)
MU   120.13 (-1.02%)
GE   154.13 (+0.28%)
CGC   6.67 (-4.44%)
DIS   113.58 (+0.56%)
AMC   2.60 (+5.26%)
PFE   25.90 (-0.04%)
PYPL   63.66 (+0.24%)
XOM   118.79 (-0.74%)
Free Trial

Pfizer (PFE) Stock Forecast & Price Target

→ “Forget Tesla, this is Elon’s Next Big Thing” (From InvestorPlace) (Ad)
Free pfe Stock Alerts
$25.87
-0.04 (-0.15%)
(As of 10:58 AM ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability

Pfizer Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Hold
Based on 17 Analyst Ratings

Analysts' Consensus Price Target

$36.88
42.54% Upside
High Forecast$50.00
Average Forecast$36.88
Low Forecast$27.00
TypeCurrent Forecast
4/17/23 to 4/16/24		1 Month Ago
3/18/23 to 3/17/24		3 Months Ago
1/17/23 to 1/17/24		1 Year Ago
4/17/22 to 4/17/23
Consensus Rating
Hold
Hold
Hold
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
6 Buy rating(s)
5 Buy rating(s)
5 Buy rating(s)
Hold
11 Hold rating(s)
10 Hold rating(s)
12 Hold rating(s)
8 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$36.88$36.88$38.22$49.80
Predicted Upside42.54% Upside15.82% Upside12.43% Upside12.94% Upside
Get Pfizer Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for PFE and its competitors with MarketBeat's FREE daily newsletter.

PFE Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

PFE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Pfizer Stock vs. The Competition

TypePfizerMedical CompaniesS&P 500
Consensus Rating Score
2.35
2.68
2.49
Consensus RatingHoldModerate BuyHold
Predicted Upside42.37% Upside881.91% Upside11.20% Upside
News Sentiment RatingPositive News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
4/15/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating		L. Chen
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated RatingOverweight ➝ Overweight$45.00+73.21%
3/22/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeBuy ➝ Hold
2/23/2024Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageBuy$36.00+30.67%
1/4/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeOutperform ➝ Market Perform$32.00+7.67%
12/14/2023Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetBuy ➝ Buy$42.00 ➝ $36.00+37.35%
12/14/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetNeutral ➝ Neutral$34.00 ➝ $27.00+2.27%
12/14/2023Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetEqual Weight ➝ Equal Weight$34.00 ➝ $28.00+5.03%
11/1/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetEqual Weight ➝ Equal Weight$39.00 ➝ $37.00+21.07%
10/16/2023BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetOutperform ➝ Outperform$44.00 ➝ $33.00-1.52%
10/16/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetNeutral ➝ Neutral$42.00 ➝ $35.00+3.80%
10/16/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetNeutral ➝ Neutral$36.00 ➝ $34.00+0.71%
10/16/2023Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetEqual Weight ➝ Equal Weight$39.00 ➝ $35.00+9.00%
10/16/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeHold ➝ Buy$38.00 ➝ $39.00+21.46%
7/14/2023HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageBuy$50.00+38.66%
6/29/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeOutperform ➝ Neutral$47.00 ➝ $40.00+10.22%
5/11/2023Daiwa Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeOutperform ➝ Neutral$38.00-0.78%
4/21/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetNeutral$50.00 ➝ $45.00+12.92%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 11:14 AM ET.

PFE Price Target - Frequently Asked Questions

What is Pfizer's consensus rating and price target?

According to the issued ratings of 17 analysts in the last year, the consensus rating for Pfizer stock is Hold based on the current 11 hold ratings and 6 buy ratings for PFE. The average twelve-month price prediction for Pfizer is $36.88 with a high price target of $50.00 and a low price target of $27.00. Learn more on PFE's analyst rating history.

Do Wall Street analysts like Pfizer more than its competitors?

Analysts like Pfizer less than other Medical companies. The consensus rating for Pfizer is Hold while the average consensus rating for medical companies is Moderate Buy. Learn more on how PFE compares to other companies.

Is Pfizer being downgraded by Wall Street analysts?

Over the previous 90 days, Pfizer's stock had 1 downgrade by analysts.

Does Pfizer's stock price have much upside?

According to analysts, Pfizer's stock has a predicted upside of 15.96% based on their 12-month stock forecasts.

What analysts cover Pfizer?

Pfizer has been rated by Argus, Cantor Fitzgerald, and Guggenheim in the past 90 days.


Stock Ratings Reports and Tools

Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (NYSE:PFE) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners
He Is Giving Away Bitcoin
Crypto Swap Profits
This Apple-like Innovator is Revolutionizing Healthcare
Wall Street Star
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research
Options trading has suddenly become more reliable.
Eagle Publishing
Top 5 AI Stocks to Buy for 2024
Market Moving Trends
The Greatest Bull Market in Crypto History…
Weiss Ratings
The #1 Crypto for 2024
InvestorPlace